EN

Rankings / Health Care

IQVIA IQV

Clinical research & healthcare data. IQVIA Holdings Inc., listed on NYSE.

Based on the FY2025 annual report (Jan 2025 – Dec 2025)

IQVIA's market cap is
about $43.65 billion.

#243 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $16.31B.

Share price (close)
$264.88
Close on Nov 5, 2026 · per share
P/E ratio
33.8x
Closing price ÷ latest annual EPS
Market cap
$43.65B
#243 of 289
Revenue
$16.31B
#180 of 299 · +5.9% YoY
Operating income
$2.182B
#155 of 231 · −0.9% YoY
Net income
$1.36B
#224 of 298 · −0.9% YoY
Free cash flow
$2.051B
#164 of 261 · −3.0% YoY
Total assets
$29.944B
#200 of 299 · +11.3% YoY
Dividends paid
—
Not reported
Dividend per share
—
Not reported
Dividend yield
—
No dividend, or a different currency
Shares outstanding
169,600,000 shares
As of Dec 31, 2025

Where the revenue went

Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.

  • Operating expenses86.6%
  • Taxes, interest & other5.0%
  • Net income8.3%

Profitability and stability

Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.

Revenue growthHow much revenue grew from the previous fiscal year
+5.9%
#184 of 299
Revenue is growing steadily. The median across 299 companies is +7.9%.
Operating marginShare of revenue kept as profit from the core business
13.4%
#152 of 231
13.4% of revenue was kept as operating profit, which is on the low side. The median across 231 companies is 19.2%.
Net marginShare of revenue left as profit after interest and taxes
8.3%
#223 of 298
After taxes, 8.3% of revenue was left as net income. The median across 298 companies is 14.0%.
FCF marginShare of revenue left as cash after capital spending
12.6%
#157 of 261
Cash is left over after capital spending. The median across 261 companies is 15.8%.
ROEHow much profit the company earned on shareholders' equity in a year
21.6%
#117 of 276
Earns a lot relative to its equity. The median across 276 companies is 16.8%.
Debt-to-equityLiabilities relative to equity. Lower means less debt
358.5%
#202 of 244
Liabilities are more than twice equity. The median across 244 companies is 159.6%.

Revenue and profit over time

Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.

FY2021 Revenue $13.874B / Net income $966M13.9B7.0%FY2021FY2022 Revenue $14.41B / Net income $1.091B14.4B7.6%FY2022FY2023 Revenue $14.984B / Net income $1.358B15.0B9.1%FY2023FY2024 Revenue $15.405B / Net income $1.373B15.4B8.9%FY2024FY2025 Revenue $16.31B / Net income $1.36B16.3B8.3%FY2025
Currency: US dollars. Years are the years in which each fiscal year ended.

Where the cash went

Unlike profit, cash flow is money that actually came in and went out.

  • Cash from operations$2.654B
  • Capital spending−$603M
  • Free cash flow (FCF)$2.051B

Whose money funds the assets

The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).

  • Total assets$29.944B
  • Total liabilities$23.314B
  • Total equity$6.503B
  • Cash and equivalents$1.98B

Compared with similar companies

Based on each company's latest annual report, so fiscal year ends may differ.

Compare in detail
CompanyAnnual revenueNet incomeRevenue growthOperating marginNet margin
IQVIAIQV$16.31B$1.36B+5.9%13.4%8.3%
WatersWAT$3.165286B$642.629M+7.0%25.4%20.3%
Agilent TechnologiesA$6.948B$1.303B+6.7%21.3%18.8%
Mettler-ToledoMTD$4.026399B$869.193M+4.0%—21.6%
DanaherDHR$24.568B$3.614B+2.9%19.1%14.7%

What the company does

IQVIA runs clinical trials on behalf of drugmakers and provides healthcare data and analytics.

The fiscal year ends around December each year.

Related companies: Waters, Agilent Technologies, Mettler-Toledo, Danaher

Financial statements

Last 5 fiscal years. Currency: US dollars.

Show the table
ItemFY2021FY2022FY2023FY2024FY2025
Revenue13.874B14.41B14.984B15.405B16.31B
Operating income1.393B1.799B1.977B2.202B2.182B
Pretax income1.128B1.363B1.459B1.669B1.591B
Net income966M1.091B1.358B1.373B1.36B
EPS (diluted)$4.95$5.72$7.29$7.49$7.84
Operating cash flow2.942B2.26B2.149B2.716B2.654B
Capital expenditures640M674M649M602M603M
Free cash flow (FCF)2.302B1.586B1.5B2.114B2.051B
Total assets24.689B25.337B26.681B26.899B29.944B
Total liabilities18.647B19.572B20.569B20.832B23.314B
Total equity6.042B5.765B6.112B6.067B6.503B
Cash and equivalents1.366B1.216B1.376B1.702B1.98B
Original filing10-K10-K10-K10-K10-K

Source: SEC EDGAR filings for IQVIA Holdings Inc. · CIK 0001478242 · US-GAAP